{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nVKORC1 encodes the vitamin K epoxide reductase complex subunit 1—a small, endoplasmic reticulum–bound, transmembrane protein that is essential for the recycling of vitamin K epoxide to vitamin K hydroquinone. This reduction reaction provides the active cofactor required for the gamma‐carboxylation of vitamin K–dependent clotting factors, which is central to normal blood coagulation. Early studies identifying VKORC1 also revealed that specific mutations within the gene can alter its enzymatic activity, contributing to aberrant responses to warfarin therapy, including cases of pharmacodynamic warfarin resistance."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "4"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nA broad array of genetic studies has since demonstrated that common VKORC1 polymorphisms—most notably promoter variants such as –1639G>A and its proxy 1173C>T, as well as coding mutations like Asp36Tyr—play a major role in determining individual sensitivity to warfarin. These variants modulate VKORC1 expression levels and, correspondingly, the efficiency of vitamin K recycling. In combination with variants in warfarin–metabolizing genes (for example, CYP2C9), VKORC1 polymorphisms account for a substantial portion of the inter–individual and inter–ethnic variability in warfarin dose requirements, with numerous studies reporting contributions of up to 50% of dose variance."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "5", "end_ref": "31"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nThe clinical translation of these insights has fostered the development of pharmacogenetic dosing algorithms that incorporate VKORC1 genotyping along with CYP2C9 status and clinical parameters (such as age, body size, and concurrent medications) to predict optimal warfarin doses. Such integrated approaches have consistently improved dose prediction, enhanced the safety of initiating and maintaining warfarin therapy, and reduced the incidence of adverse events like over–anticoagulation and bleeding. Collectively, these studies firmly establish VKORC1 not only as a key enzyme in vitamin K metabolism but also as a critical biomarker for personalized anticoagulant therapy."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "32", "end_ref": "50"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature02214"}], "href": "https://doi.org/10.1038/nature02214"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "14765194"}], "href": "https://pubmed.ncbi.nlm.nih.gov/14765194"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Tao Li, Chun-Yun Chang, Da-Yun Jin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification of the gene for vitamin K epoxide reductase."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature02254"}], "href": "https://doi.org/10.1038/nature02254"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "14765195"}], "href": "https://pubmed.ncbi.nlm.nih.gov/14765195"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Dominic J Harrington, Sarah Underwood, Colin Morse, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Thromb Haemost (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1160/TH04-08-0540"}], "href": "https://doi.org/10.1160/TH04-08-0540"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15630486"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15630486"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Sol Schulman, Belinda Wang, Weikai Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Proc Natl Acad Sci U S A (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1073/pnas.1009972107"}], "href": "https://doi.org/10.1073/pnas.1009972107"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20696932"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20696932"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Giovanna D'Andrea, Rosa Lucia D'Ambrosio, Pasquale Di Perna, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2004-06-2111"}], "href": "https://doi.org/10.1182/blood-2004-06-2111"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15358623"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15358623"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Laurent Bodin, Céline Verstuyft, David-Alexandre Tregouet, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2005-01-0341"}], "href": "https://doi.org/10.1182/blood-2005-01-0341"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15790782"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15790782"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "M Wadelius, L Y Chen, K Downes, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Common VKORC1 and GGCX polymorphisms associated with warfarin dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics J (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.tpj.6500313"}], "href": "https://doi.org/10.1038/sj.tpj.6500313"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15883587"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15883587"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Hsiang-Yu Yuan, Jin-Jer Chen, M T Michael Lee, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddi180"}], "href": "https://doi.org/10.1093/hmg/ddi180"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15888487"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15888487"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Mark J Rieder, Alexander P Reiner, Brian F Gage, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "N Engl J Med (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1056/NEJMoa044503"}], "href": "https://doi.org/10.1056/NEJMoa044503"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15930419"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15930419"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Elizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2005-03-1108"}], "href": "https://doi.org/10.1182/blood-2005-03-1108"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15947090"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15947090"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "David L Veenstra, Joyce H S You, Mark J Rieder, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.fpc.0000174789.77614.68"}], "href": "https://doi.org/10.1097/01.fpc.0000174789.77614.68"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16141794"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16141794"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Christof Geisen, Matthias Watzka, Katja Sittinger, et al. "}, {"type": "b", "children": [{"type": "t", "text": "VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Thromb Haemost (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1160/TH05-04-0290"}], "href": "https://doi.org/10.1160/TH05-04-0290"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16270629"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16270629"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Harumi Takahashi, Grant R Wilkinson, Edith A Nutescu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.fpc.0000184955.08453.a8"}], "href": "https://doi.org/10.1097/01.fpc.0000184955.08453.a8"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16424822"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16424822"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Taisei Mushiroda, Yozo Ohnishi, Susumu Saito, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Hum Genet (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s10038-005-0354-5"}], "href": "https://doi.org/10.1007/s10038-005-0354-5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16432637"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16432637"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Soo-Chin Lee, Swee-Siang Ng, Johannes Oldenburg, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clpt.2005.11.006"}], "href": "https://doi.org/10.1016/j.clpt.2005.11.006"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16513444"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16513444"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Yibo Wang, Weili Zhang, Yuhui Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection)."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Circulation (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/CIRCULATIONAHA.105.580167"}], "href": "https://doi.org/10.1161/CIRCULATIONAHA.105.580167"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16549638"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16549638"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Christina L Aquilante, Taimour Y Langaee, Larry M Lopez, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clpt.2005.11.011"}], "href": "https://doi.org/10.1016/j.clpt.2005.11.011"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16580898"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16580898"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Tom Schalekamp, Bjorn P Brassé, Janine F M Roijers, et al. "}, {"type": "b", "children": [{"type": "t", "text": "VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clpt.2006.04.006"}], "href": "https://doi.org/10.1016/j.clpt.2006.04.006"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16815313"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16815313"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "Kyoko Obayashi, Katsunori Nakamura, Junichi Kawana, et al. "}, {"type": "b", "children": [{"type": "t", "text": "VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clpt.2006.04.010"}], "href": "https://doi.org/10.1016/j.clpt.2006.04.010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16890578"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16890578"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Lai-San Tham, Boon-Cher Goh, Anne Nafziger, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clpt.2006.06.009"}], "href": "https://doi.org/10.1016/j.clpt.2006.06.009"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17015052"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17015052"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "Mia Wadelius, Leslie Y Chen, Niclas Eriksson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of warfarin dose with genes involved in its action and metabolism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Genet (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00439-006-0260-8"}], "href": "https://doi.org/10.1007/s00439-006-0260-8"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17048007"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17048007"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Rina Kimura, Kotaro Miyashita, Yoshihiro Kokubo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Thromb Res (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.thromres.2006.09.007"}], "href": "https://doi.org/10.1016/j.thromres.2006.09.007"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17049586"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17049586"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Ronen Loebstein, Ilana Dvoskin, Hillel Halkin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2006-08-038984"}], "href": "https://doi.org/10.1182/blood-2006-08-038984"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17110455"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17110455"}]}, {"type": "r", "ref": 24, "children": [{"type": "t", "text": "John F Carlquist, Benjamin D Horne, Joseph B Muhlestein, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Thromb Thrombolysis (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s11239-006-9030-7"}], "href": "https://doi.org/10.1007/s11239-006-9030-7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17111199"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17111199"}]}, {"type": "r", "ref": 25, "children": [{"type": "t", "text": "A-K Hamberg, M-L Dahl, M Barban, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.clpt.6100084"}], "href": "https://doi.org/10.1038/sj.clpt.6100084"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17301738"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17301738"}]}, {"type": "r", "ref": 26, "children": [{"type": "t", "text": "Yusheng Zhu, Michael Shennan, Kristen K Reynolds, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Chem (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1373/clinchem.2006.078139"}], "href": "https://doi.org/10.1373/clinchem.2006.078139"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17510308"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17510308"}]}, {"type": "r", "ref": 27, "children": [{"type": "t", "text": "N A Limdi, G McGwin, J A Goldstein, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.clpt.6100290"}], "href": "https://doi.org/10.1038/sj.clpt.6100290"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17653141"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17653141"}]}, {"type": "r", "ref": 28, "children": [{"type": "t", "text": "Liyan Miao, Jian Yang, Chenrong Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Clin Pharmacol (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00228-007-0381-6"}], "href": "https://doi.org/10.1007/s00228-007-0381-6"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17899045"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17899045"}]}, {"type": "r", "ref": 29, "children": [{"type": "t", "text": "Jeffrey L Anderson, Benjamin D Horne, Scott M Stevens, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Circulation (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/CIRCULATIONAHA.107.737312"}], "href": "https://doi.org/10.1161/CIRCULATIONAHA.107.737312"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17989110"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17989110"}]}, {"type": "r", "ref": 30, "children": [{"type": "t", "text": "M-S Wen, Mtm Lee, J-J Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.clpt.6100453"}], "href": "https://doi.org/10.1038/sj.clpt.6100453"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18183038"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18183038"}]}, {"type": "r", "ref": 31, "children": [{"type": "t", "text": "Stuart A Scott, Lisa Edelmann, Ruth Kornreich, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Hum Genet (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ajhg.2007.10.002"}], "href": "https://doi.org/10.1016/j.ajhg.2007.10.002"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18252229"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18252229"}]}, {"type": "r", "ref": 32, "children": [{"type": "t", "text": "B F Gage, C Eby, J A Johnson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/clpt.2008.10"}], "href": "https://doi.org/10.1038/clpt.2008.10"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18305455"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18305455"}]}, {"type": "r", "ref": 33, "children": [{"type": "t", "text": "Ute I Schwarz, Marylyn D Ritchie, Yuki Bradford, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic determinants of response to warfarin during initial anticoagulation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "N Engl J Med (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1056/NEJMoa0708078"}], "href": "https://doi.org/10.1056/NEJMoa0708078"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18322281"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18322281"}]}, {"type": "r", "ref": 34, "children": [{"type": "t", "text": "Alan H B Wu, Ping Wang, Andrew Smith, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/14622416.9.2.169"}], "href": "https://doi.org/10.2217/14622416.9.2.169"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18370846"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18370846"}]}, {"type": "r", "ref": 35, "children": [{"type": "t", "text": "Nita A Limdi, Donna K Arnett, Joyce A Goldstein, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/14622416.9.5.511"}], "href": "https://doi.org/10.2217/14622416.9.5.511"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18466099"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18466099"}]}, {"type": "r", "ref": 36, "children": [{"type": "t", "text": "Danxin Wang, Huizi Chen, Kathryn M Momary, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2008-03-144899"}], "href": "https://doi.org/10.1182/blood-2008-03-144899"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18523153"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18523153"}]}, {"type": "r", "ref": 37, "children": [{"type": "t", "text": "Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2008-01-134247"}], "href": "https://doi.org/10.1182/blood-2008-01-134247"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18535201"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18535201"}]}, {"type": "r", "ref": 38, "children": [{"type": "t", "text": "Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The largest prospective warfarin-treated cohort supports genetic forecasting."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2008-04-149070"}], "href": "https://doi.org/10.1182/blood-2008-04-149070"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18574025"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18574025"}]}, {"type": "r", "ref": 39, "children": [{"type": "t", "text": "J A Perini, C J Struchiner, E Silva-Assunção, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/clpt.2008.166"}], "href": "https://doi.org/10.1038/clpt.2008.166"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18754001"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18754001"}]}, {"type": "r", "ref": 40, "children": [{"type": "t", "text": "Sheng-Wen Huang, Hai-Sheng Chen, Xian-Qun Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/FPC.0b013e328326e0c7"}], "href": "https://doi.org/10.1097/FPC.0b013e328326e0c7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19177029"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19177029"}]}, {"type": "r", "ref": 41, "children": [{"type": "t", "text": "Paola Borgiani, Cinzia Ciccacci, Vittorio Forte, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/14622416.10.2.261"}], "href": "https://doi.org/10.2217/14622416.10.2.261"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19207028"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19207028"}]}, {"type": "r", "ref": 42, "children": [{"type": "t", "text": "Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pgen.1000433"}], "href": "https://doi.org/10.1371/journal.pgen.1000433"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19300499"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19300499"}]}, {"type": "r", "ref": 43, "children": [{"type": "t", "text": "Martina Teichert, Mark Eijgelsheim, Fernando Rivadeneira, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A genome-wide association study of acenocoumarol maintenance dosage."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddp309"}], "href": "https://doi.org/10.1093/hmg/ddp309"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19578179"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19578179"}]}, {"type": "r", "ref": 44, "children": [{"type": "t", "text": "L H Cavallari, T Y Langaee, K M Momary, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic and clinical predictors of warfarin dose requirements in African Americans."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/clpt.2009.223"}], "href": "https://doi.org/10.1038/clpt.2009.223"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20072124"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20072124"}]}, {"type": "r", "ref": 45, "children": [{"type": "t", "text": "Nita A Limdi, Mia Wadelius, Larisa Cavallari, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2009-12-255992"}], "href": "https://doi.org/10.1182/blood-2009-12-255992"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20203262"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20203262"}]}, {"type": "r", "ref": 46, "children": [{"type": "t", "text": "Robert S Epstein, Thomas P Moyer, Ronald E Aubert, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Am Coll Cardiol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.jacc.2010.03.009"}], "href": "https://doi.org/10.1016/j.jacc.2010.03.009"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20381283"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20381283"}]}, {"type": "r", "ref": 47, "children": [{"type": "t", "text": "Stuart A Scott, Rame Khasawneh, Inga Peter, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/pgs.10.49"}], "href": "https://doi.org/10.2217/pgs.10.49"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20504253"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20504253"}]}, {"type": "r", "ref": 48, "children": [{"type": "t", "text": "Nita A Limdi, Mohit A Limdi, Larisa Cavallari, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Warfarin dosing in patients with impaired kidney function."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Kidney Dis (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1053/j.ajkd.2010.05.023"}], "href": "https://doi.org/10.1053/j.ajkd.2010.05.023"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20709439"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20709439"}]}, {"type": "r", "ref": 49, "children": [{"type": "t", "text": "Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddq389"}], "href": "https://doi.org/10.1093/hmg/ddq389"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20833655"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20833655"}]}, {"type": "r", "ref": 50, "children": [{"type": "t", "text": "Andrea L Jorgensen, Richard J FitzGerald, James Oyee, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0044064"}], "href": "https://doi.org/10.1371/journal.pone.0044064"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22952875"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22952875"}]}]}]}